Wells Fargo & Co set a $43.00 target price on Mylan (NASDAQ:MYL) in a report issued on Thursday morning. The firm currently has a hold rating on the stock.
MYL has been the topic of several other research reports. UBS Group restated a buy rating and issued a $46.00 target price on shares of Mylan in a research note on Thursday, October 5th. Instinet restated a buy rating and issued a $37.00 target price on shares of Mylan in a research note on Thursday, October 5th. Citigroup set a $42.00 target price on shares of Mylan and gave the company a buy rating in a research note on Wednesday, October 4th. Mizuho restated a buy rating and issued a $37.00 target price on shares of Mylan in a research note on Wednesday, October 4th. Finally, ValuEngine upgraded shares of Mylan from a hold rating to a buy rating in a research note on Monday, October 2nd. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. Mylan has an average rating of Buy and a consensus price target of $44.19.
Mylan (MYL) traded up $0.22 on Thursday, reaching $46.73. 7,815,925 shares of the company’s stock were exchanged, compared to its average volume of 4,563,909. Mylan has a 1 year low of $29.39 and a 1 year high of $47.25. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.46 and a quick ratio of 0.95. The firm has a market capitalization of $25,067.65, a P/E ratio of 29.02, a P/E/G ratio of 1.48 and a beta of 1.38.
Mylan (NASDAQ:MYL) last posted its quarterly earnings results on Monday, November 6th. The company reported $1.10 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.20 by ($0.10). Mylan had a return on equity of 20.63% and a net margin of 7.28%. The business had revenue of $2.99 billion for the quarter, compared to analyst estimates of $3.09 billion. During the same quarter in the prior year, the firm earned $1.38 EPS. The firm’s quarterly revenue was down 2.3% on a year-over-year basis. analysts forecast that Mylan will post 4.55 earnings per share for the current fiscal year.
In related news, CEO Heather M. Bresch sold 75,000 shares of Mylan stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $45.00, for a total value of $3,375,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.69% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its holdings in shares of Mylan by 12.0% in the second quarter. Vanguard Group Inc. now owns 32,880,790 shares of the company’s stock valued at $1,276,432,000 after buying an additional 3,531,974 shares during the last quarter. Pzena Investment Management LLC raised its holdings in Mylan by 84.1% during the 3rd quarter. Pzena Investment Management LLC now owns 22,721,384 shares of the company’s stock worth $712,770,000 after purchasing an additional 10,381,697 shares during the last quarter. State Street Corp raised its holdings in Mylan by 1.6% during the 2nd quarter. State Street Corp now owns 20,498,541 shares of the company’s stock worth $795,751,000 after purchasing an additional 321,977 shares during the last quarter. Greenlight Capital Inc. raised its holdings in Mylan by 0.4% during the 3rd quarter. Greenlight Capital Inc. now owns 10,744,307 shares of the company’s stock worth $337,048,000 after purchasing an additional 42,600 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. raised its holdings in Mylan by 7.5% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 6,922,373 shares of the company’s stock worth $268,726,000 after purchasing an additional 480,500 shares during the last quarter. 74.90% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This report was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/01/21/wells-fargo-co-analysts-give-mylan-myl-a-43-00-price-target.html.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.